451 related articles for article (PubMed ID: 20350136)
1. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
3. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
[TBL] [Abstract][Full Text] [Related]
4. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
5. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.
de Vos A; van der Weide J; Loovers HM
Pharmacogenomics J; 2011 Oct; 11(5):359-67. PubMed ID: 20531370
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19.
Holmgren P; Carlsson B; Zackrisson AL; Lindblom B; Dahl ML; Scordo MG; Druid H; Ahlner J
J Anal Toxicol; 2004 Mar; 28(2):94-104. PubMed ID: 15068562
[TBL] [Abstract][Full Text] [Related]
7. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
Ng C; Sarris J; Singh A; Bousman C; Byron K; Peh LH; Smith DJ; Tan CH; Schweitzer I
Hum Psychopharmacol; 2013 Sep; 28(5):516-22. PubMed ID: 24014145
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 variation and citalopram response.
Mrazek DA; Biernacka JM; O'Kane DJ; Black JL; Cunningham JM; Drews MS; Snyder KA; Stevens SR; Rush AJ; Weinshilboum RM
Pharmacogenet Genomics; 2011 Jan; 21(1):1-9. PubMed ID: 21192344
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
11. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
Tsuchimine S; Ochi S; Tajiri M; Suzuki Y; Sugawara N; Inoue Y; Yasui-Furukori N
Ther Drug Monit; 2018 Jun; 40(3):356-361. PubMed ID: 29570504
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
14. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.
Uckun Z; Baskak B; Ozel-Kizil ET; Ozdemir H; Devrimci Ozguven H; Suzen HS
J Clin Pharm Ther; 2015 Dec; 40(6):672-9. PubMed ID: 26343256
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic Assessment of Drug Metabolic Pathways and P-Glycoprotein in Patients Treated With Antidepressants in an Ambulatory Setting.
Lloret-Linares C; Bosilkovska M; Daali Y; Gex-Fabry M; Heron K; Bancila V; Michalopoulos G; Perroud N; Richard-Lepouriel H; Aubry JM; Desmeules J; Besson M
J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29570971
[TBL] [Abstract][Full Text] [Related]
16. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.
Rudberg I; Mohebi B; Hermann M; Refsum H; Molden E
Clin Pharmacol Ther; 2008 Feb; 83(2):322-7. PubMed ID: 17625515
[TBL] [Abstract][Full Text] [Related]
17. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
19. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.
Kuo HW; Liu SC; Tsou HH; Liu SW; Lin KM; Lu SC; Hsiao MC; Hsiao CF; Liu CY; Chen CH; Lu ML; Shen WW; Tang HS; Liu SI; Chang LH; Wu HY; Chang YS; Yeh TK; Chen ACh; Liu YL
Pharmacogenomics; 2013 Jul; 14(10):1191-201. PubMed ID: 23859573
[TBL] [Abstract][Full Text] [Related]
20. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
